Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The E-site of the 60S eukaryotic ribosomal subunit is a critical functional domain within the large ribosomal subunit responsible for the release of deacylated tRNA during protein synthesis (Wilson & Doudna Cate, 2012). As one of the three primary tRNA binding sites (A, P, and E), the E-site facilitates the final stage of the translation elongation cycle by holding the tRNA after its amino acid has been added to the growing polypeptide chain (Garreau de Loubresse et al., 2014). This site is structurally complex, involving interactions between ribosomal RNA (rRNA) and various ribosomal proteins, and its proper functioning is essential for the translocation of the mRNA-tRNA complex. In clinical and research contexts, the 60S E-site is a significant pharmacological target; for instance, the antifungal agent Sordarin selectively inhibits fungal protein synthesis by stabilizing the interaction between elongation factor 2 (eEF2) and the E-site (Justice et al., 1998). Similarly, the laboratory tool cycloheximide exerts its inhibitory effects by binding directly to this site, preventing the release of tRNA and halting translation (Schneider-Poetsch et al., 2010). Understanding the E-site's architecture and dynamics is vital for developing selective inhibitors that can distinguish between fungal and human ribosomes, thereby addressing infectious diseases while minimizing host toxicity. Dysregulation of ribosomal function at this site is also implicated in various ribosomopathies and the hyper-proliferative state of cancer cells (Robert et al., 2009).
Inhibition of translation elongation by blocking deacylated tRNA release or stabilizing elongation factor binding to the exit site (Schneider-Poetsch et al., 2010; Justice et al., 1998).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E-site of the 60S eukaryotic ribosomal subunit (60S E-site).